Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase I/II Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT01505868 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT01505868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01505868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase I/II Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Completed
Start date
July 11, 2012
Completion date
December 9, 2019
Enrollment
170 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

castration levels of testosterone, castration-resistant prostate carcinoma, lymphadenopathy, metastatic prostate carcinoma, prostate adenocarcinoma, prostate carcinoma metastatic in the bone, prostate small cell carcinoma